Vertex Pharmaceuticals Inc. | Large-cap | Healthcare
$450.27
1.52%
| Vertex Stock Comparison:
Vertex vs RegeneronVertex vs AlnylamVertex vs Royalty Pharma plcVertex vs InsmedVertex vs IncyteVertex vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 11.0B
Gross Profit 9.5B 86.11%
Operating Income 4.4B 39.88%
Net Income -535.6M -4.86%
EPS (Diluted) -$2.08

Balance Sheet Metrics

Total Assets 22.5B
Total Liabilities 6.1B
Shareholders Equity 16.4B
Debt to Equity 0.37

Cash Flow Metrics

Operating Cash Flow -562.9M
Free Cash Flow -978.0M

Revenue & Profitability Trend

Vertex Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 11.0B 9.9B 8.9B 7.6B 6.2B
Cost of Goods Sold 1.5B 1.3B 1.1B 904.2M 736.3M
Gross Profit 9.5B 8.6B 7.9B 6.7B 5.5B
Operating Expenses 5.1B 4.3B 3.5B 2.8B 2.6B
Operating Income 4.4B 4.3B 4.4B 3.9B 2.9B
Pre-tax Income 248.5M 4.4B 4.2B 2.7B 3.1B
Income Tax 784.1M 760.2M 910.4M 388.3M 405.2M
Net Income -535.6M 3.6B 3.3B 2.3B 2.7B
EPS (Diluted) -$2.08 $13.89 $12.82 $9.01 $10.29

Income Statement Trend

Vertex Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 9.6B 14.1B 13.2B 9.6B 8.1B
Non-Current Assets 12.9B 8.6B 4.9B 3.9B 3.6B
Total Assets 22.5B 22.7B 18.2B 13.4B 11.8B
Liabilities
Current Liabilities 3.6B 3.5B 2.7B 2.1B 1.9B
Non-Current Liabilities 2.6B 1.6B 1.5B 1.2B 1.2B
Total Liabilities 6.1B 5.1B 4.2B 3.3B 3.1B
Equity
Total Shareholders Equity 16.4B 17.6B 13.9B 10.1B 8.7B

Balance Sheet Composition

Vertex Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -535.6M 3.6B 3.3B 2.3B 2.7B
Operating Cash Flow -562.9M 3.7B 3.8B 2.4B 3.7B
Investing Activities
Capital Expenditures -297.7M -200.4M -204.7M -235.0M -259.8M
Investing Cash Flow -3.6B -3.1B -321.1M -340.9M 99.4M
Financing Activities
Dividends Paid - - - - -
Financing Cash Flow -1.6B -696.8M -250.5M -1.6B -770.2M
Free Cash Flow -978.0M 3.3B 3.9B 2.4B 3.0B

Cash Flow Trend

Vertex Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 32.82
Forward P/E 23.66
Price to Book 6.92
Price to Sales 10.28
PEG Ratio 23.66

Profitability Ratios

Profit Margin -8.91%
Operating Margin 37.22%
Return on Equity -5.64%
Return on Assets 11.77%

Financial Health

Current Ratio 2.65
Debt to Equity 10.00
Beta 0.42

Per Share Data

EPS (TTM) -$3.83
Book Value per Share $64.20
Revenue per Share $43.09

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
vrtx 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Alnylam 40.8B - 353.42 -414.62% -11.49% 2,358.26
Royalty Pharma plc 20.3B 14.75 2.30 18.00% 48.26% 77.82
Insmed 20.0B - 193.43 -320.20% -265.93% 1,316.96
Incyte 13.0B 336.30 3.55 0.47% 0.48% 1.18

Financial data is updated regularly. All figures are in the company's reporting currency.